Close Menu

NEW YORK (GenomeWeb) – T2 Biosystems has entered into a $50 million debt facility agreement with CRG.

The firm will initially draw $40 million and can take out the rest through July 27, 2018, based on certain operating milestones.

T2 Bio said in a statement that it will use approximately $28 million to retire existing debt facilities and promissory notes. The remainder will be used for general corporate purposes, as working capital, and to fund strategic priorities.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.